Reduction in Depressive Symptoms in People who Inject Drugs who Are Cured of Hepatitis C Virus Infection: The HERO Study
Irene Pericot‐Valverde(Clemson University), Irene Soloway(Clemson University), Virginia Lijewski, Syeda Raji, Juhi Moon, Oluwaseun Falade‐Nwulia, Taniya Silva(Albert Einstein College of Medicine), Brianna L. Norton(Albert Einstein College of Medicine), Shruti H. Mehta(Johns Hopkins University), Paula J. Lum(West Virginia University), William A. Schmitt, Moonseong Heo(Columbia University), Judith Feinberg(Johns Hopkins University), Julia H. Arnsten(Montefiore Medical Center), Jennifer Hidalgo, Snehal Lopes(Clemson University), Jillian M. Roche, Paul Meißner, Joelle Brown(University of California, San Francisco), Courtney Borsuk, Kiara Lora, Alison Karasz(University of Massachusetts Chan Medical School), Shadi Nahvi(Albert Einstein College of Medicine), James F. Thrasher(University of South Carolina), Alain H. Litwin(Prisma Health), Michael Fingerhood, Judith I. Tsui(University of Washington), Taryn Haselhuhn, Sergio Fernández‐Artamendi(Universidad de Sevilla), Angela Mason(Harvard University), Linda Agyemang(Albert Einstein College of Medicine), Lynn E. Taylor(University of Rhode Island), Kimberly Page(University of New Mexico), Yngvild Olsen, Hagan Walker(Albert Einstein College of Medicine), and Ashley Coleman, Anita Pitts, Hope Koene(Albert Einstein College of Medicine), and Vickie Walters, F. Evans, Arthur Y Kim(Harvard University), Brian E. Dickerson
Cited by 4
Related Papers
Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection
|Clinical Infectious Diseases|2018|726
Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: Role of hepatitis C and B infections
|Hepatology|2002|521
Protection against persistence of hepatitis C
|The Lancet|2002|439
Hepatitis C Virus Infection and Incident Type 2 Diabetes
|Hepatology|2003|405